# 1 Identification of immunodominant linear epitopes from SARS-

# 2 CoV-2 patient plasma

- 3
- 4 Lluc Farrera-Soler<sup>1</sup>, Jean-Pierre Daguer<sup>1</sup>, Sofia Barluenga<sup>1</sup>, Patrick Cohen<sup>2</sup>, Sabrina
- 5 Pagano<sup>2</sup>, Sabine Yerly<sup>2</sup>, Laurent Kaiser<sup>2,3</sup>, Nicolas Vuilleumier<sup>2</sup>, Nicolas Winssinger<sup>1</sup>\*
- 6
- 1 Department of Organic Chemistry, NCCR Chemical Biology, Faculty of Science,
   University of Geneva, Geneva, Switzerland.
- 9
- 10 **2** Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals
- 11 and Faculty of Medicine, Geneva, Switzerland
- 12
- 13 **3** Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine,
- 14 Geneva, Switzerland
- 15
- 16 \* Corresponding author
- 17 E-mail: Nicolas.Winssinger@unige.ch

#### 18 Abstract

A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) is the source of a current pandemic (COVID-19) with devastating consequences in public health and economic stability. Using a peptide array to map the antibody response of plasma from healing patients, we identified immunodominant linear epitopes corresponding to key proteolytic sites on the spike protein.

24

### 25 Introduction

On December 2019, a novel infectious disease causing pneumonia-like symptoms was identified in the city of Wuhan in the province of Hubei (China) [1]. This new coronavirus infectious disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is having a devastating impact on public health and economic stability on a global scale [2]. The World Health Organization declared it a pandemic on the 11<sup>th</sup> March 2020.

32 Mapping the epitopes corresponding to the immune system's antibody response 33 against the virus is important for vaccine development [3, 4], diagnostic serological 34 tests [4] as well as for identifying neutralizing antibodies with therapeutic potential [5]. 35 Indeed, epitope mapping of the SARS-CoV-1 revealed immunodominant epitopes and 36 identified neutralizing antibodies [6-13]. However, the observation of antibody-37 dependent enhancement (ADE) of SARS-CoV-1 in non-human primates is concerning 38 and should be considered for vaccine development [14, 15]. While ADE mechanisms 39 arising from binding-only antibodies (non-neutralizing) are well documented, an ADE 40 mechanism with neutralizing antibodies for the related MERS-CoV was also

reported[16]. In this case, it was shown that neutralizing antibodies targeting the
receptor-binding domain (RBD) of the virus redirected viral entry to Fc-expressing cells,
broadening the host-targeted cells. Thus, antibodies generated by vaccination against
SARS-CoV-2 could enhance viral entry instead of offering protection, leading to
vaccine-associated enhanced respiratory disease (VARED) [17].

The homology between SARS-CoV-1 and SARS-CoV-2 rapidly led to the hypothesis 46 47 that neutralizing antibodies identified from patients in the SARS-CoV-1 in the 2003 48 epidemic could also be neutralizing SARS-CoV-2 [18, 19]. Other antibodies with 49 neutralizing activities have been discovered through different methodologies [20-25]. 50 The rapid propagation of SARS-CoV-2 stimulated several studies predicting the 51 antigenic parts of the viral proteins in silico [26-32], and analyzing SARS-CoV-1 52 epitopes that were conserved in this new coronavirus [33-36]. More recently, the first 53 reports of experimental epitope mapping of the SARS-CoV-2 were deposited on 54 repositories [37-42].

Herein we report the preparation of a microarray to map the antibody response to linear epitopes of the spike protein of SARS-CoV-2 and the analysis of 12 laboratory confirmed COVID-19 cases and 6 negative controls using the described peptide microarray.

59

#### 60 Materials and methods

#### 61 Plasma specimens from COVID-19 and healthy patients.

Anonymized leftovers of whole blood-EDTA were used for this method evaluation, in accordance with our institution's ethical committee and national regulations. We included 12 real-time RT-PCR confirmed COVID-19 cases hospitalized at the University

65	Hospitals of Geneva, and 6 unmatched negative blood samples from asymptomatic
66	donors, obtained during the same period (April 2020). Analyses (see below) were
67	performed within 72h of blood sampling without any freezing-thawing cycle.
68	
69	SARS-CoV-2 RT-PCR analyses and SARS-CoV-2 lgG serology
70	As previously published [43], SARS-CoV-2 RT-PCR was performed according to
71	manufacturers' instructions on various platforms, including BD SARS-CoV-2 reagent kit
72	for BD Max system (Becton, Dickinson and Co, US) and Cobas 6800 SARS-CoV-2 RT-PCR
73	(Roche, Switzerland).
74	SARS-CoV-2 IgG serology against the S1-domain of the spike protein of SARS-CoV-2 was
75	assessed using the CE-marked Euroimmun IgG ELISA (Euroimmun AG, Lübeck,
76	Germany # EI 2606-9601 G). EDTA-plasma was diluted at 1:101 and assessed with the
77	IgG ELISA according to the manufacturer's instructions and has been extensively
78	reported elsewhere [43]. Median time from RT-PCR to serology testing was 3 weeks,
79	reason why sample were considered as healing rather than convalescent plasma. All
80	the 12 COVID-19 samples were considered as reactive against SARS-CoV-2.
81	

#### 82 Synthesis of the peptide-PNA conjugate library.

The library of peptide-PNA conjugate was synthesized by automated synthesis on an Intavis peptide synthesizer as previously described [44, 45]. The synthesis was initiated with the peptide followed by the PNA tag using a capping cycle after each coupling. Hence, truncated peptides cannot hybridize on the microarray since they will not have the necessary tag. A library of 200 linear peptides was constructed based on the sequences of the spike ectodomain protein from SARS-CoV-2 (residues 1-1213-

93	Microarray epitope mapping.
92	
91	identified by MALDI analysis. See SI for full synthetic details and characterization data.
90	(12mer) with an overlap of 6 residues. Each peptide-PNA conjugate was positively
89	Gene Bank: QHD43416.1), fragmenting the protein into two sets of 100 peptides

94 Microarrays were obtained from Agilent (Custom microarray slides, Agilent 95 ref:0309317100-100002). Each peptide-PNA is complementary to a DNA sequence 96 that is present 23 times at random positions on the array.

97 The arrays were incubated with plasma (1:150 dilution) for 1 hour at room 98 temperature, washed with PBS-T and dried by centrifugation prior to the next step. 99 The arrays were then incubated with Cy-3 labeled goat anti-human IgG (ab97170 from 100 Abcam, 1:500 dilution) for 30 min, washed with PBS-T and dried by centrifugation for 101 scanning. See SI for detailed procedures.

102 The fluorescence intensity on the array was measured on a GenePix 4100A 103 microarray scanner using the median value of fluorescent intensity. The data for each 104 peptide (23 spots) was plotted as a heat map of the median value from the 23 spots. 105 The high redundancy in the measurements and the use of a median function insures 106 that artifacts from a microarray experiment do not contribute to the consolidated 107 data.

108

#### 109 Validation of epitope 655-672.

110 The peptide was synthesized according to the same protocol as for the library111 synthesis, replacing the PNA tag with a biotin.

<u>Fluorescent bead assay</u>: 0.3  $\mu$ L of Pierce<sup>TM</sup> High-Capacity Streptavidin Agarose 112 Beads (catalog n°: 20357 from Thermo Scientific<sup>TM</sup>) were mixed with 50  $\mu$ L of the 113 114 biotinylated peptide  $10\mu M$  in PBS- T. The beads were incubated for 20 minutes and thereafter blocked with 200  $\mu$ L of Fetal bovine serum for 10 minutes. The beads were 115 then washed once with 100  $\mu$ L PBS-T and 5  $\mu$ L of serum from either positive or 116 117 negative patients was added together with 450  $\mu$ L of PBS-T and 50  $\mu$ L of fetal bovine 118 serum in order to block unspecific interactions. The beads were then incubated for 90 119 minutes and subsequently washed 4 times with 100  $\mu$ L of PBS-T in order to remove all 120 the non-binders. Finally, 200  $\mu$ L of a 163nM solution of anti-human IgG-FITC (ab6854 121 from Abcam) in PBS-T with 0.5% BSA was added and incubated for 1 hour. The excess 122 of secondary antibody was washed away using 3 times 100  $\mu$ L of PBS-T and finally the 123 beads were imaged with a Leica SP8 inverted confocal microscope.

124 By Enzyme-Linked Immunosorbent Assay (ELISA): A solution of Streptavidin (ref: S0677 from Sigma Aldrich), 100 μL of an 80nM, in PBS was added to a Corning<sup>®</sup> 96-125 126 well Clear Flat Bottom Polystyrene High Bind Microplate (catalog nº: 9018 from 127 Corning) and incubated overnight at 4°C. The plate was then washed three times with 128  $300 \ \mu L$  of PBS-T (60 seconds, room temperature) and  $200 \ \mu L$  of an 800 nM solution of 129 biotinylated peptide in PBS-T was added and incubated for 90 minutes at 36°C. The 130 plate was then blocked with 300 µL of PBS-T with 0.5% non-fat dry milk (60 minutes at 36°C). The plate was washed 3 times with 300  $\mu$ L of PBS-T (60 seconds, room 131 132 temperature) and a 1:300 diluted plasma in PBS-T-0.5% non-fat dry milk was added to 133 each well and incubated for 90 minutes at 36°C. After incubation of the plasma, the plate was washed 3 times with 300  $\mu$ L PBS-T (60 seconds, room temperature), 1 time 134 with PBS-T 0.5% non-fat dry milk (60 minutes, 37°C) and again 3 times with 300  $\mu$ L 135

136	PBS-T (60 seconds, room temperature). 100 $\mu$ L of Goat Anti-Human-IgG HRP
137	conjugated (ab97175 from Abcam) 1:10000 diluted in PBS-T 0.5% BSA were added to
138	each well and incubated for 90 minutes at 37°C. The plate was then washed 3 times
139	with PBS-T (60 seconds, room temperature) and 200 $\mu L$ of a 0.41mM solution of
140	3,312,5,512-Tetramethylbenzidine (TMB) (ref: 860336 from Sigma Aldrich) in 50mM
141	Na <sub>2</sub> HPO <sub>4</sub> , 25mM citric acid and 0.0024% $H_2O_2$ , pH 5.5 solution was added to the plate
142	and incubated for 20 minutes at 37 °C. Finally, 50 $\mu L$ of a 1M sulfuric acid solution were
143	added and the absorbance was measured at 450nm with a plate reader (SpectroMax,
144	Molecular Device). For each sample, triplicates were performed and the fluorescence
145	value are the average of the 3 reads.

146

#### 147 Sequence alignment .

148 Sequence alignment was done using Clustal Omega [46].

149

### 150 **Results and discussion**

151 SARS-CoV-2 is composed of 4 major structural proteins: S (spike), M (membrane), N (nucleocapsid) and E (envelope) [47-49]. The spike protein is responsible for entry by 152 153 binding the angiotensin-converting enzyme 2 (ACE 2) on the host cell [50, 51]. 154 Accordingly, antibodies that bind the RBD and inhibit the interaction of the S protein 155 with ACE 2 have been the center of attention. Based on the critical role of the S 156 protein in CoV infection, we focused our work on this protein, dissecting it into two 157 sets of overlapping linear 12mer peptides (two-fold sequence coverage with 6AA 158 overlap between the two sets; i.e 1-12, 7-18, 13-24,...). The peptide array was 159 prepared by hybridization of PNA-tagged peptide library onto a DNA microarray

(Figure 1) [52]. This technology insures a high level of homogeneity across different arrays since individual arrays are prepared from the same library hybridized onto commercial DNA microarrays. Furthermore, the arrays are designed to have each sequence present 23 times, thus insuring high accuracy by calculating the median of the observed fluorescence of the 23 spots.

165 The S protein of SARS-CoV-2 shares 76% homology with the SARS-CoV-1, [48, 53] and this homology has already been harnessed to predict epitopes based on 166 167 experimental results from SARS-CoV-1. However, the different infection outcome of SARS-CoV-2 relative to SARS-CoV-1 originates in part from differences in the S protein. 168 169 SARS-CoV-2 has better affinity to ACE 2 than SARS-CoV-1, yielding more efficient 170 cellular entry [54, 55]. Furthermore, the presence of a furin cleavage site [56-58] in 171 the S protein of SARS-CoV-2 (not present in SARS-CoV-1) coupled to an extended loop 172 at the proteolytic site leads to higher cleavage efficacy thus facilitating its activation 173 for membrane fusion [55, 59-61].

174 Analysis of 12 different plasma samples from SARS-CoV-2 infected patients and 175 comparison to 6 samples from uninfected patients clearly highlighted a strong 176 response to specific epitopes (Figure 2). The three linear epitopes most abundantly 177 detected (SARS-CoV-2 S protein) were: 655-672, 787-822, and 1147-1158. None of 178 these epitopes was singularly detected in all the positive samples tested, but each is detected in >40% of the positive patients. The 655-672 epitope is the most detected in 179 180 positive samples and corresponds to a peptide that is not part of a secondary 181 structures (Fig 3A-B). The corresponding epitope had been also detected in SARS-CoV-1 [8] (89% homology for the 18mer peptide, Fig 4A-C) and predicted bioinformatically 182 183 for SARS-CoV-2 [27, 31, 35, 36]; however, it had yet to be observed experimentally.

184 Interestingly, this epitope is just next to the reported S1/S2 cleavage site (Fig 4A-C, 185 furin/TMPRSS2) [50, 57]. The proteolytic cleavage of the loop 681-685 has been 186 demonstrated to be necessary for the viral entry into the host cell [50]. Moreover, the 187 proteolytic cleavage of the S protein could be a determinant factor for the capacity of 188 the virus to cross species. For example, the S protein of Uganda bats MERS-like CoV is capable of binding human cells, but this is insufficient for entry [62]. However, if a 189 190 protease (trypsin) is added the protein is cleaved and viral entry occurs. Furthermore, 191 the most closely related virus to SARS-CoV-2 is RaTG-13 from a bat found in Yunnan 192 province in 2013 which does not contain the furin cleavage sequence [49]. Taken 193 together, this evidence suggest that cleavage of the S protein is a barrier to zoonotic 194 coronavirus transmission. Incorporation of the furin cleavage sites could have been 195 acquired by recombination with another virus leading to human infection. In relation 196 to the furin cleavage site, the pathogenic avian H5N1 contains such a furin cleavage 197 site that leads to higher pathogenicity due to the distribution of furins in multiple 198 tissues [63]. We speculate that the binding of an antibody to the epitope 655-672 199 would sterically block the proteolysis of S1/S2 and should thus be broadly neutralizing, 200 since the proteolysis is required for viral entry, without promoting ADE.

Another epitope abundantly detected only in healing patients was the 787-822, a peptide segment extending at the periphery of the solvent exposed part of the protein (Fig 3A-B). It has also been experimentally observed in the SARS-CoV-1 [9, 13], SARS-CoV-2 [38, 39] and predicted bioinformatically [26, 27, 30, 31, 33, 36]. Interestingly, this epitope includes the S2' cleavage site of the spike protein (Fig 4D-F), which has been reported to activate the protein for membrane fusion via extensive irreversible conformational changes [53, 64]. This epitope also includes the fusion peptide (816-

208 833, Fig 4D-F) [65] which is highly conserved among coronaviruses [66, 67], suggesting 209 a potential pan-coronavirus epitope at this location. It should be noted that a peptide-210 based fusion inhibitor was shown to exhibit broad inhibitory activity across multiple 211 human CoVs [68] and that antibodies against that region have shown neutralizing 212 activity in SARS-CoV-1 [69]. Taken together, the data support the fact that antibodies 213 inhibiting this proteolytic cleavage should be neutralizing [61, 65].

Finally, the epitope 1147-1158 is found at the C terminus of the spike protein. The structural data reported thus far did not suggest a defined structure for this portion of the S protein. This epitope extends from the helix bundle 1140-1147 (Fig 3A-B) and had also been experimentally observed in SARS-CoV-1 [9] and predicted bioinformatically for SARS-CoV-2 [27, 31, 35].

One limitation of epitope mapping with a peptide array is that it is restricted to linear epitopes. Antibodies binding to the RBD have been shown to participate in interactions spanning multiple peptide fragments. Indeed, we did not observe a strong response to linear peptides in the RBD. A control experiment with Al334/CR3022 antibody [25, 70] showed only weak binding to 367-378 peptide sequence of the RBD.

To validate the results observed on the microarray, a peptide (655-672) was synthesized as a biotin conjugate for pull-down and ELISA experiments. The sequence corresponding to 655-672-biotin and a scrambled version of the biotinylated peptide were individually immobilized on agarose streptavidin beads. Beads were exposed to serum from patients that were either positive or negative for that epitope based on the microarray data and subsequently treated with anti-Human-IgG-FITC. The fluorescence of the beads was quantified by confocal microscopy (Fig 5A). As can be

232 seen in Fig 5B-E, the beads with 655-672 peptide and positive serum sample showed 233 higher fluorescence than the ones with either negative serum or using the scrambled 234 peptide. To further probe the binding of 655-672 peptide to antibodies of SARS-CoV-2 235 positive patients, the same 655-672 biotinylated peptide was used in an ELISA assay 236 (Fig 6A). Three SARS-CoV-2 positive samples showing strong 655-672 signal (Samples 237 7, 8 and 9) and three SARS-CoV-2 negative samples (Samples 14, 15 and 17) were 238 analyzed showing clear binding to the 655-672 peptide and not to the scrambled 239 version (Fig 6B).

240 Next, an alanine scan was performed to assess the contribution of individual amino 241 acids to the interaction with the antibodies of two of the COVID positive patients 242 containing antibodies for this epitope (Sample number 1 and 6) at two different 243 dilutions (1 to 100 and 1 to 400). For this purpose, 17 different peptide-PNA 244 conjugates were synthesized, replacing one amino acid at the time with Ala (Fig 7A) 245 and measuring the intensity of the observed binding on the microarray. This analysis 246 revealed the key role of 5 residues that, if converted to Ala, lead to dramatic loss of 247 activity (amino acids in blue, Fig 7B). Thus, the key amino acids crucial for binding with 248 the antibodies common for these two plasma samples are H655, Y660, C662, G669 and 249 C671. The binding of the antibody presents in sample 1 also seems to depend on the 250 P665. The remarkable similarities between the two patients is notable considering a polyclonal response. 251

252

#### 253 Conclusion

We have developed a peptide array for the epitope mapping of the spike protein of SARS-CoV-2. Using this array to profile healing plasma of twelve laboratory confirmed

256 COVID-19 patients and six negative controls we have discovered three 257 immunodominant linear regions, each present in >40% of COVID-19 patient. Two of 258 these epitopes correspond to key proteolytic sites on the spike protein (S1/S2 and the 259 S2') which have been shown to be crucial for viral entry and play an important role in 260 virus evolution and infection. The fact that antibodies binding to the protease 261 cleavage sites were identified from COVID-19 patients raises the possibility that other 262 mechanism than blocking the RBD-ACE2 interaction could be harnessed for 263 neutralization. Furthermore, blocking proteolytic cleavage could be important to 264 reduce antibody-dependent enhancement of viral entry, a key feature for vaccine 265 development. Full characterization of these antibodies is necessary, and efforts on this 266 direction are on their way.

267

#### 268 Acknowledgement

269 The authors gratefully acknowledge funding from the University of Geneva and the

270 département d'instruction public du canton de Genève. The authors also gratefully

271 acknowledge Prof. Cosson from the Geneva Antibody Facility for generous gift of

272 reagents, and Isabelle Arm-Vernez from the virology laboratory of the laboratory

273 medicine division for the assessment of routine SARS-CoV-2 IgG serology.

274

#### 275 References

- 276 1. Cohen J, Normile D. New SARS-like virus in China triggers alarm. Science.
- 2020;367(6475):234-5. Epub 2020/01/18. doi: 10.1126/science.367.6475.234. PubMed
  PMID: 31949058.

279 2. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-

economic implications of the coronavirus pandemic (COVID-19): A review.

281 International Journal of Surgery. 2020;78:185-93. doi:

282 <u>https://doi.org/10.1016/j.ijsu.2020.04.018</u>.

283 3. Jacob CO, Leitner M, Zamir A, Salomon D, Arnon R. Priming immunization 284 against cholera toxin and E. coli heat-labile toxin by a cholera toxin short peptide-beta-285 galactosidase hybrid synthesized in E. coli. EMBO J. 1985;4(12):3339-43. Epub 286 1985/12/01. PubMed PMID: 3004953; PubMed Central PMCID: PMCPMC554663. 287 4. Ahmad TA, Eweida AE, Sheweita SA. B-cell epitope mapping for the design of 288 vaccines and effective diagnostics. Trials in Vaccinology. 2016;5:71-83. doi: 289 https://doi.org/10.1016/j.trivac.2016.04.003. 290 5. Sawyer LA. Antibodies for the prevention and treatment of viral diseases. 291 Antiviral Res. 2000;47(2):57-77. Epub 2000/09/21. doi: 10.1016/s0166-3542(00)00111-292 x. PubMed PMID: 10996394. 293 6. Babcock GJ, Esshaki DJ, Thomas WD, Jr., Ambrosino DM. Amino acids 270 to 294 510 of the severe acute respiratory syndrome coronavirus spike protein are required 295 for interaction with receptor. J Virol. 2004;78(9):4552-60. Epub 2004/04/14. doi: 296 10.1128/jvi.78.9.4552-4560.2004. PubMed PMID: 15078936; PubMed Central PMCID: 297 PMCPMC387703. 298 7. Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, et al. Neutralizing epitopes 299 of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb 300 technology. MAbs. 2010;2(1):53-66. Epub 2010/02/20. doi: 10.4161/mabs.2.1.10788. 301 PubMed PMID: 20168090; PubMed Central PMCID: PMCPMC2828578. 302 Guo JP, Petric M, Campbell W, McGeer PL. SARS corona virus peptides 8. 303 recognized by antibodies in the sera of convalescent cases. Virology. 2004;324(2):251-304 6. Epub 2004/06/23. doi: 10.1016/j.virol.2004.04.017. PubMed PMID: 15207612; 305 PubMed Central PMCID: PMCPMC7125913. 306 9. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, et al. Identification of 307 immunodominant sites on the spike protein of severe acute respiratory syndrome 308 (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J 309 Immunol. 2004;173(6):4050-7. Epub 2004/09/10. doi: 10.4049/jimmunol.173.6.4050. 310 PubMed PMID: 15356154. 311 Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, et al. An exposed domain in 10. 312 the severe acute respiratory syndrome coronavirus spike protein induces neutralizing 313 antibodies. J Virol. 2004;78(13):7217-26. Epub 2004/06/15. doi: 314 10.1128/JVI.78.13.7217-7226.2004. PubMed PMID: 15194798; PubMed Central 315 PMCID: PMCPMC421657. 316 11. Chou TH, Wang S, Sakhatskyy PV, Mboudjeka I, Lawrence JM, Huang S, et al. 317 Epitope mapping and biological function analysis of antibodies produced by 318 immunization of mice with an inactivated Chinese isolate of severe acute respiratory 319 syndrome-associated coronavirus (SARS-CoV). Virology. 2005;334(1):134-43. Epub 320 2005/03/08. doi: 10.1016/j.virol.2005.01.035. PubMed PMID: 15749129; PubMed 321 Central PMCID: PMCPMC7111783. 322 12. van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, 323 et al. Molecular and biological characterization of human monoclonal antibodies 324 binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome 325 coronavirus. J Virol. 2005;79(3):1635-44. Epub 2005/01/15. doi: 326 10.1128/JVI.79.3.1635-1644.2005. PubMed PMID: 15650189; PubMed Central PMCID: 327 PMCPMC544131. 328 Zhong X, Yang H, Guo ZF, Sin WY, Chen W, Xu J, et al. B-cell responses in 13. 329 patients who have recovered from severe acute respiratory syndrome target a

330 dominant site in the S2 domain of the surface spike glycoprotein. J Virol. 331 2005;79(6):3401-8. Epub 2005/02/26. doi: 10.1128/JVI.79.6.3401-3408.2005. PubMed 332 PMID: 15731234; PubMed Central PMCID: PMCPMC1075701. 333 Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, et al. Immunodominant SARS 14. Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on 334 335 Infection in Non-human Primates. ACS Infect Dis. 2016;2(5):361-76. Epub 2016/09/15. 336 doi: 10.1021/acsinfecdis.6b00006. PubMed PMID: 27627203; PubMed Central PMCID: 337 PMCPMC7075522. 338 Garber K. Coronavirus vaccine developers wary of errant antibodies. 2020. doi: 15. 339 10.1038/d41587-020-00016-w. 340 Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular Mechanism for 16. 341 Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020;94(5). Epub 342 2019/12/13. doi: 10.1128/JVI.02015-19. PubMed PMID: 31826992; PubMed Central 343 PMCID: PMCPMC7022351. 344 Graham BS. Rapid COVID-19 vaccine development. Science. 17. 345 2020;368(6494):945-6. Epub 2020/05/10. doi: 10.1126/science.abb8923. PubMed 346 PMID: 32385100. 347 Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-18. 348 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 349 2020. Epub 2020/05/19. doi: 10.1038/s41586-020-2349-y. PubMed PMID: 32422645. 350 Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, et al. A 19. 351 human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 352 2020;11(1):2251. Epub 2020/05/06. doi: 10.1038/s41467-020-16256-y. PubMed PMID: 353 32366817; PubMed Central PMCID: PMCPMC7198537. 354 20. Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent neutralizing antibodies 355 against SARS-CoV-2 identified by high-throughput single-cell sequencing of 356 convalescent patients' B cells. Cell. 2020. Epub 2020/05/20. doi: 357 10.1016/j.cell.2020.05.025. PubMed PMID: 32425270; PubMed Central PMCID: 358 PMCPMC7231725. 359 21. Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, et al. Identification of Human Single-360 Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 2020. Epub 2020/05/16. 361 doi: 10.1016/j.chom.2020.04.023. PubMed PMID: 32413276; PubMed Central PMCID: 362 PMCPMC7224157. 363 22. Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, et al. 364 Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. 365 bioRxiv. 2020:2020.05.12.091298. doi: 10.1101/2020.05.12.091298. 366 Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody 23. 367 targets the receptor binding site of SARS-CoV-2. Nature. 2020. Epub 2020/05/27. doi: 368 10.1038/s41586-020-2381-y. PubMed PMID: 32454512. 369 24. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. A noncompeting pair of 370 human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. 371 Science. 2020. Epub 2020/05/15. doi: 10.1126/science.abc2241. PubMed PMID: 372 32404477; PubMed Central PMCID: PMCPMC7223722. 373 Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, et al. A highly conserved cryptic 25. 374 epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020. 375 Epub 2020/04/05. doi: 10.1126/science.abb7269. PubMed PMID: 32245784; PubMed 376 Central PMCID: PMCPMC7164391.

377 26. Khan A, Alam A, Imam N, Siddigui MF, Ishrat R. Design of an Epitope-Based 378 Peptide Vaccine against the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-379 CoV-2): A Vaccine Informatics Approach. bioRxiv. 2020:2020.05.03.074930. doi: 380 10.1101/2020.05.03.074930. 381 Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, et al. 27. 382 Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-383 COV-2): Immunoinformatics approach. J Med Virol. 2020. Epub 2020/02/29. doi: 384 10.1002/jmv.25736. PubMed PMID: 32108359. 385 Mitra D, Shekhar N, Pandey J, Jain A, Swaroop S. Multi-epitope based peptide 28. 386 vaccine design against SARS-CoV-2 using its spike protein. bioRxiv. 387 2020:2020.04.23.055467. doi: 10.1101/2020.04.23.055467. 388 Fast E, Chen B. Potential T-cell and B-cell Epitopes of 2019-nCoV. bioRxiv. 29. 389 2020:2020.02.19.955484. doi: 10.1101/2020.02.19.955484. 390 Gao A, Chen Z, Segal FP, Carrington M, Streeck H, Chakraborty AK, et al. 30. 391 Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2. bioRxiv. 392 2020:2020.05.14.095885. doi: 10.1101/2020.05.14.095885. 393 Parvez S, Preeti S. Prediction of T and B Cell Epitopes in the Proteome of SARS-31. 394 CoV-2 for Potential Use in Diagnostics and Vaccine Design2020. 395 32. Li L, Sun T, He Y, Li W, Fan Y, Zhang J. Epitope-based peptide vaccine design and 396 target site characterization against novel coronavirus disease caused by SARS-CoV-2. 397 bioRxiv. 2020:2020.02.25.965434. doi: 10.1101/2020.02.25.965434. 398 33. Forcelloni S, Benedetti A, Dilucca M, Giansanti A. Identification of conserved 399 epitopes in SARS-CoV-2 spike and nucleocapsid protein. bioRxiv. 400 2020:2020.05.14.095133. doi: 10.1101/2020.05.14.095133. 401 34. Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike 402 glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 2020. Epub 403 2020/03/07. doi: 10.1038/s41423-020-0385-z. PubMed PMID: 32132669. 404 35. Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential 405 Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV 406 Immunological Studies. Viruses. 2020;12(3). Epub 2020/02/29. doi: 407 10.3390/v12030254. PubMed PMID: 32106567; PubMed Central PMCID: 408 PMCPMC7150947. 409 36. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence 410 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune 411 Responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671-80 e2. Epub 2020/03/19. 412 doi: 10.1016/j.chom.2020.03.002. PubMed PMID: 32183941; PubMed Central PMCID: 413 PMCPMC7142693. 414 Zhang B-z, Hu Y-f, Chen L-l, Tong Y-g, Hu J-c, Cai J-p, et al. Mapping the 37. 415 Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines 416 against COVID-19. bioRxiv. 2020:2020.04.23.056853. doi: 10.1101/2020.04.23.056853. 417 38. Wang H, Hou X, Wu X, Liang T, Zhang X, Wang D, et al. SARS-CoV-2 proteome 418 microarray for mapping COVID-19 antibody interactions at amino acid resolution. 419 bioRxiv. 2020:2020.03.26.994756. doi: 10.1101/2020.03.26.994756. 420 Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY-P, Chee RS-L, et al. Potent 39. 421 neutralizing antibodies in the sera of convalescent COVID-19 patients are directed 422 against conserved linear epitopes on the SARS-CoV-2 spike protein. bioRxiv. 423 2020:2020.03.30.015461. doi: 10.1101/2020.03.30.015461.

424 40. Jegouic SM, Loureiro S, Thom M, Paliwal D, Jones IM. Recombinant SARS-CoV-2 spike proteins for sero-surveillance and epitope mapping. bioRxiv. 425 2020:2020.05.21.109298. doi: 10.1101/2020.05.21.109298. 426 427 Jiang H-w, Li Y, Zhang H-n, Wang W, Men D, Yang X, et al. Global profiling of 41. 428 SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray. 429 medRxiv. 2020:2020.03.20.20039495. doi: 10.1101/2020.03.20.20039495. 430 42. Krishnamurthy HK, Jayaraman V, Krishna K, Rajasekaran KE, Wang T, Bei K, et al. 431 Antibody Profiling and Prevalence in the US population during the SARS-CoV2 432 Pandemic. medRxiv. 2020:2020.04.29.20085068. doi: 10.1101/2020.04.29.20085068. 433 43. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. 434 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-435 POP): a population-based study. The Lancet. doi: 10.1016/S0140-6736(20)31304-0. 436 44. Zambaldo C, Barluenga S, Winssinger N. PNA-encoded chemical libraries. Curr 437 Opin Chem Biol. 2015;26:8-15. doi: 10.1016/j.cbpa.2015.01.005. PubMed PMID: 438 WOS:000357352400003. 439 Chouikhi D, Ciobanu M, Zambaldo C, Duplan V, Barluenga S, Winssinger N. 45. 440 Expanding the Scope of PNA-Encoded Synthesis (PES): Mtt-Protected PNA Fully Orthogonal to Fmoc Chemistry and a Broad Array of Robust Diversity-Generating 441 442 Reactions. Chem-Eur J. 2012;18(40):12698-704. doi: 10.1002/chem.201201337. 443 PubMed PMID: WOS:000309238400020. 444 Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, et al. The EMBL-46. 445 EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 446 2019;47(W1):W636-W41. Epub 2019/04/13. doi: 10.1093/nar/gkz268. PubMed PMID: 447 30976793; PubMed Central PMCID: PMCPMC6602479. 448 47. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus 449 associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. 450 Epub 2020/02/06. doi: 10.1038/s41586-020-2008-3. PubMed PMID: 32015508; 451 PubMed Central PMCID: PMCPMC7094943. 452 Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and 48. epidemiology of 2019 novel coronavirus: implications for virus origins and receptor 453 454 binding. Lancet. 2020;395(10224):565-74. Epub 2020/02/03. doi: 10.1016/S0140-455 6736(20)30251-8. PubMed PMID: 32007145; PubMed Central PMCID: 456 PMCPMC7159086. 457 49. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia 458 outbreak associated with a new coronavirus of probable bat origin. Nature. 459 2020;579(7798):270-3. Epub 2020/02/06. doi: 10.1038/s41586-020-2012-7. PubMed 460 PMID: 32015507; PubMed Central PMCID: PMCPMC7095418. 461 50. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 462 463 Proven Protease Inhibitor. Cell. 2020;181(2):271-80 e8. Epub 2020/03/07. doi: 464 10.1016/j.cell.2020.02.052. PubMed PMID: 32142651; PubMed Central PMCID: 465 PMCPMC7102627. 466 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of 51. SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-8. Epub 467 468 2020/03/07. doi: 10.1126/science.abb2762. PubMed PMID: 32132184; PubMed

469 Central PMCID: PMCPMC7164635.

470 52. Harris JL, Winssinger N. PNA encoding (PNA = peptide nucleic acid): From 471 solution-based libraries to organized microarrays. Chem-Eur J. 2005;11(23):6792-801. doi: 10.1002/chem.200500305. PubMed PMID: WOS:000233508800001. 472 473 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, 53. 474 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 475 2020;181(2):281-92 e6. Epub 2020/03/11. doi: 10.1016/j.cell.2020.02.058. PubMed 476 PMID: 32155444; PubMed Central PMCID: PMCPMC7102599. 477 54. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM 478 structure of the 2019-nCoV spike in the prefusion conformation. Science. 479 2020;367(6483):1260-3. Epub 2020/02/23. doi: 10.1126/science.abb2507. PubMed PMID: 32075877; PubMed Central PMCID: PMCPMC7164637. 480 481 Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms 55. 482 of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727-34. Epub 2020/05/08. 483 doi: 10.1073/pnas.2003138117. PubMed PMID: 32376634; PubMed Central PMCID: 484 PMCPMC7260975. 485 56. Cyranoski D. Profile of a killer virus. Nature. 2020;581:22-6. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike 486 57. glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site 487 488 absent in CoV of the same clade. Antiviral Res. 2020;176:104742. Epub 2020/02/15. 489 doi: 10.1016/j.antiviral.2020.104742. PubMed PMID: 32057769; PubMed Central 490 PMCID: PMCPMC7114094. 491 58. Wang Q, Qiu Y, Li JY, Zhou ZJ, Liao CH, Ge XY. A Unique Protease Cleavage Site 492 Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) 493 Potentially Related to Viral Transmissibility. Virol Sin. 2020. Epub 2020/03/22. doi: 494 10.1007/s12250-020-00212-7. PubMed PMID: 32198713; PubMed Central PMCID: 495 PMCPMC7091172. 496 59. Meng T, Cao H, Zhang H, Kang Z, Xu D, Gong H, et al. The insert sequence in 497 SARS-CoV-2 enhances spike protein cleavage by TMPRSS. bioRxiv. 498 2020:2020.02.08.926006. doi: 10.1101/2020.02.08.926006. 499 60. Jaimes JA, Andre NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic Analysis 500 and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct 501 and Proteolytically Sensitive Activation Loop. J Mol Biol. 2020;432(10):3309-25. Epub 502 2020/04/23. doi: 10.1016/i.jmb.2020.04.009. PubMed PMID: 32320687; PubMed 503 Central PMCID: PMCPMC7166309. 504 Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane 61. 505 fusion mechanism offers a potential target for antiviral development. Antiviral 506 Research. 2020;178:104792. doi: https://doi.org/10.1016/j.antiviral.2020.104792. 507 Menachery VD, Dinnon KH, 3rd, Yount BL, Jr., McAnarney ET, Gralinski LE, Hale 62. A, et al. Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. J 508 509 Virol. 2020;94(5). Epub 2019/12/06. doi: 10.1128/JVI.01774-19. PubMed PMID: 510 31801868; PubMed Central PMCID: PMCPMC7022341. 511 Luczo JM, Tachedjian M, Harper JA, Payne JS, Butler JM, Sapats SI, et al. 63. 512 Evolution of high pathogenicity of H5 avian influenza virus: haemagglutinin cleavage 513 site selection of reverse-genetics mutants during passage in chickens. Sci Rep. 514 2018;8(1):11518. Epub 2018/08/03. doi: 10.1038/s41598-018-29944-z. PubMed PMID:

515 30068964; PubMed Central PMCID: PMCPMC6070550.

516 64. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The

517 novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the

518 cellular protease TMPRSS2 for entry into target cells. bioRxiv.

519 2020:2020.01.31.929042. doi: 10.1101/2020.01.31.929042.

- 520 65. Zhu Y, Yu D, Yan H, Chong H, He Y. Design of potent membrane fusion inhibitors
- against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. bioRxiv.

522 2020:2020.03.26.009233. doi: 10.1101/2020.03.26.009233.

523 66. Madu IG, Roth SL, Belouzard S, Whittaker GR. Characterization of a highly

524 conserved domain within the severe acute respiratory syndrome coronavirus spike
525 protein S2 domain with characteristics of a viral fusion peptide. J Virol.

526 2009;83(15):7411-21. Epub 2009/05/15. doi: 10.1128/JVI.00079-09. PubMed PMID:

527 19439480; PubMed Central PMCID: PMCPMC2708636.

528 67. Alsaadi EAJ, Neuman BW, Jones IM. A Fusion Peptide in the Spike Protein of

529 MERS Coronavirus. Viruses. 2019;11(9). Epub 2019/09/08. doi: 10.3390/v11090825.

530 PubMed PMID: 31491938; PubMed Central PMCID: PMCPMC6784214.

531 68. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, et al. A pan-coronavirus

fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv.

533 2019;5(4):eaav4580. Epub 2019/04/17. doi: 10.1126/sciadv.aav4580. PubMed PMID:
534 30989115; PubMed Central PMCID: PMCPMC6457931.

535 69. Miyoshi-Akiyama T, Ishida I, Fukushi M, Yamaguchi K, Matsuoka Y, Ishihara T, et

al. Fully human monoclonal antibody directed to proteolytic cleavage site in severe

acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a

538 rhesus macaque SARS model. J Infect Dis. 2011;203(11):1574-81. Epub 2011/05/20.

doi: 10.1093/infdis/jir084. PubMed PMID: 21592986; PubMed Central PMCID:

540 PMCPMC7107252.

54170.Hammel P, Marchetti A, Lima WC, Lau K, Pojer F, Hacker D, et al. Al334 and542AQ806 antibodies recognize the spike S protein from SARS-CoV-2 by ELISA. bioRxiv.

543 2020:2020.05.08.084103. doi: 10.1101/2020.05.08.084103.

544

## 545 Supporting information

546 Detailed procedures and physical characterization of the synthetic products.



- 549 Fig 1. Schematic representation of the 200 membered Peptide-PNA epitope library
- 550 design, DNA Microarray generation and experimental approach to map the antibody
- response of COVID-19 patients to the S protein of SARS-CoV-2.

552



#### 553 554

555

556 Fig 2. Antibody response from 12 convalescent SARS-CoV-2 patients and 6 uninfected 557 negative controls. A: Domains of the spike protein (SP = Signal peptide, NTD = Nterminal domain, RBD = Receptor-binding domain, FP = Fusion Peptide, IFP = internal 558 fusion protein, HR1 = Heptad repeat 1, HR2 = Heptad repeat 2) and heat map of 559 560 antibody binding to the peptide fragments (black background intensity, red 5x 561 background intensity and yellow 10x background intensity). Sample number are 562 indicated on the left of the heat map. B: Fluorescence intensity of antibody binding 563 from the 12 SARS-CoV-2 positive samples (left) and 6 SARS-CoV-2 negative samples 564 The fluorescence intensities are the median of 23 values followed by (right) 565 normalization to the background intensity. The immunodominant regions are 566 highlighted with the corresponding residue numbers (the epitope numbers correspond 567 to the column on top of the dash).

- 568
- 569



- 570
- 571 Fig 3. A) Localization of the three selected epitopes on the crystal structure of SARS-
- 572 CoV-2 Spike protein (PDB ID: 6VYB): red (epitope 655-672), green (epitope 787-822) 573 and orange (epitope 1147-1158, the structure is undefined in the PDB). B) Zoom of the
- 574 3 selected epitopes.
- 575



576 577

578 Fig 4. Selected epitopes localization in relation to the protease cleavage site of the spike protein. A-B) The 655-672 epitope (red) and the two reported protease cleavage 579 580 sites S1/S2: site 1 (685-686: blue) and site 2 (695-696: cyano). C) Sequence alignment 581 of the S1/S2 cleavage sites for five different coronaviruses SARSCov2(2019), SARSCov (2003), HCovHKU1, HCovNL63, HCOVOC43 and HCov229E. D-E) The 787-822 epitope 582 583 (green) and the S2' cleavage site (815-816: magenta). F) Sequence alignment of the S2' 584 cleavage site. Figure generated from pdb ID: 6VXX. 585





Fig 5. A) Schematic representation of epitope validation (anti-Spike-655-672 lgG in the 588 589 SARS-CoV-2 positive patients' plasma). Microscope images of the beads with: B) Biotin 590 655-672 with Positive plasma; C) Biotin 655-672 with Negative plasma; D) Biotin-591 scrambled peptide with Positive plasma. E) FITC fluorescence quantification of B, C and 592 D.



593

Fig 6. A) Schematic representation of the ELISA assay. B) ELISA assay with 3 different 655-672 positive samples with the 655-672 peptide and scrambled peptide and 3 negative samples. Error bars represent triplicate experiments.

597



598

Fig 7. Alanine scan by hybridization of PNA-peptide conjugates Ala-1 to Ala-17 to a DNA microarray. A) Peptide sequences of the 17 PNA-peptide conjugates used for the alanine scan, where one amino acid at the time is modified by an alanine. B) Heat map of the interaction of 655-672 positive patient plasma with the different peptides-PNA conjugates hybridized in the DNA array at two different dilutions (1 to 100 and 1 to 400). Heat map represents the normalized fluoresce average of 23 different spots in the array.